# To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

> **NCT05856487** · PHASE3 · UNKNOWN · sponsor: **NVP Healthcare** · enrollment: 228 (estimated)

## Conditions studied

- Cardiovascular Diseases

## Interventions

- **DRUG:** NVP-2203
- **DRUG:** NVP-2203-R1
- **DRUG:** NVP-2203-R2
- **DRUG:** NVP-2203-R3
- **DRUG:** NVP-2203 Placebo
- **DRUG:** NVP-2203-R1 Placebo
- **DRUG:** NVP-2203-R2 Placebo
- **DRUG:** NVP-2203-R3 Placebo

## Key facts

- **NCT ID:** NCT05856487
- **Lead sponsor:** NVP Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-30
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05856487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05856487, "To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05856487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*